Abstract:Background: FTY720 is a novel immunomodulator that may provide an opportunity for a reduction in calcineurin inhibitor dosage in transplant recipients with renal/hepatic side effects. However, the effects of FTY720 on renal or hepatic hemodynamics are unknown. The aim of this study was to establish the hemodynamic and renal actions of FTY720 at therapeutically relevant dosages. Methods: The effects of acute and repeat oral administration of FTY720 on systemic, renal, and hepatic hemodynamics were investigated in the anesthetized male Lewis rat. Renal function and renal tubular parameters were examined in animals that received repeat high dosage of FTY720. Results: Seven-day oral administration of FTY720 did not cause any significant changes in markers of hepatocyte injury, nor did it cause any reduction in renal function (elevated urea and creatinine). Histological examination of liver and kidney from animals treated with repeat FTY720 for 1 or 3 weeks did not reveal any sclerosis, tubular changes, infiltrates, or fibrosis. Hepatocyte, vascular, and biliary structures were normal. Compared with the vehicle (saline), oral administration of FTY720 at dosages up to 5 mg/kg/day for 1 week did not have any significant effects on systemic, hepatic, or renal hemodynamics. Five min after intravenous FTY720 administration (1 mg/kg), mean arterial pressure (MAP) rose to 114+/-3.3% of baseline (P <0.01) before returning to the normal range within 30-45 min. Lower doses of FTY720 (0.3 and 0.5 mg/kg, i.v.) did not affect MAP. Renal cortical perfusion, renal artery blood flow, and renal vascular resistance were not altered by FTY720 at i.v. doses up to 1 mg/kg. Animals that received FTY720 (5 mg/kg/day) for 3 weeks showed a significant reduction in body weight (-4.8+/-1% of baseline at 3 weeks, P <0.001); however, weight-adjusted creatinine clearance, 24 h urine production, and urine osmolality were not different from those in control animals (0.71+/-0.1 vs. 0.74+/-0.1 ml/min/100 g, 2.63+/-0.2 vs. 3.12+/-0.2 ml/100 g, and 2003+/-33 vs. 1966+/-56 mOsm/kg, respectively). FTY720 at the same repeat oral dosage was, nevertheless, associated with a significantly lower 24 h sodium excretion and a significantly lower fractional excretion of sodium compared with those in control animals (223.4+/-35 vs. 304.5+/-50 micromol/100 g and 1.75+/-0.3 vs. 2.23+/-0.3%, respectively; P <0.05). Conclusions: Our data indicate that, at least in the short term, oral FTY720 does not cause any significant adverse effects on renal or hepatic hemodynamics, nor does it cause any reduction in glomerular perfusion and thus may provide reasonable rescue/add-on therapy in calcineurin-inhibitor treated transplant recipients. At high repeat oral dosages, however, FTY720 may alter renal handling of sodium.

Fty720 Attenuates Tubulointerstitial Inflammation And Fibrosis In Subtotally Nephrectomized Rats

FTY720 Inhibits Tubulointerstitial Inflammation in Albumin Overload-Induced Nephropathy of Rats Via the Sphk1 Pathway

FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease

[Effect of FTY720 on Glomerulosclerosis and Expression of Cell Cycle Regulatory Proteins in Subtotally Nephrectomized Rats].

FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF-β signalling in fibroblasts

Renoprotective effect of FYT720 on Tacrolimus-inducing renal injury

Effect of FTY720 on Chronic Cyclosporine Nephropathy in Rats.

Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction.

Treatment of renal interstitial fibrosis with an agonistic Tie2 monoclonal antibody via amelioration of peritubular capillary lesions in a mouse model of nephropathy

Effects of FTY720 on Peripheral Blood Lymphocytes and Graft Infiltrating Cells in a Rat Model of Chronic Renal Allograft Rejection.

Targeting tubulointerstitial remodeling in proteinuric nephropathy in rats

Fluorofenidone Attenuates Tubulointerstitial Fibrosis by Inhibiting TGF-β1-Induced Fibroblast Activation

The Protective Mechanism of Fluorofenidone in Renal Interstitial Inflammation and Fibrosis

Tubulointerstitial Expression of Thrombosondin-1 in 5/6 Renal Ablation Rats

FFNT25 Ameliorates Unilateral Ureteral Obstruction-Induced Renal Fibrosis.

Experimental Study of the Therapeutic Effect and Mechanism of "shenxian Fuyuan Capsule" on Chronic Renal Failure in Rats

Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats

Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat

The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis

Reduction of Renal Interstitial Fibrosis by Targeting Tie2 in Vascular Endothelial Cells

Correction: Norcantharidin Inhibits Renal Interstitial Fibrosis by Blocking the Tubular Epithelial-Mesenchymal Transition